KDR and hepatocellular carcinoma: Nivolumab with cabozantinib, a multi-kinase inhibitor with activity against VEGFR2, was studied in the neoadjuvant setting with the goal of converting unresectable HCC to resectable and increasing antitumor immunity (40).